Stocks | | | Healthcare stocks are a sector of the stock market that attracts many investors. Whether you’re interested in the best growth stocks or the biggest stock gainers, healthcare stocks can be a good addition to your portfolio. The overall health of the market is likely to improve, due to new technology and an aging population. Read the Full Story |
|
From Our Partners | | AI breakthroughs. Inflation shocks. Energy rotations.
The market is moving fast — and the biggest winners often start small.
At Street Ideas, we focus on small-cap companies showing early momentum — before the crowd piles in. | | “3 Under-the-Radar Stocks Triggering Early Signals” |
|
Stocks | | | Healthcare stocks are big right now and are some of the most active stocks monitored by traders. For those looking to invest in this growing market, hospital stocks may be a good place to start. The industry shows a lot of potential, due to technological advances, an aging population, and even a perceived mental health crisis related to gun violence. However, there are also plenty of factors that may have a major impact on the industry, such as regulations that affect health plans, coverage, insurance companies, and whether the government might repeal the Affordable Care Act (ACA) insurance. These potential concerns do not mean that investors must avoid the industry, it simply means that investors should understand the investments they’re making and ensure that hospital stocks are only a part of their diversified portfolio. Read the Full Story |
|
Markets | | |
On Nov. 13, Foot Locker (NYSE:FL) stock got a boost when Nike (NYSE:NKE) announced that they will stop selling their shoes on Amazon (NASDAQ:AMZN). FL stock jumped over 2% on the news during the day’s trading session, closing at $46.38. The stock has since given back the gains, but are there... Read the Full Story |
|
From Our Partners | | Bitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity.
While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video. | | Watch the Bitcoin Skimming strategy here |
|
Stocks | | |
Shares of Nvidia (NASDAQ: NVDA) were trading down 4% at one point during Friday’s session following the company’s fiscal third-quarter earnings release on Thursday evening.
The California based company is known for producing the graphics processing units and chips used in the gaming, ... Read the Full Story |
|
Markets | | | In this era of algorithm-driven financial markets, stock prices can be volatile and extreme. Often a stock price overreaction (steep sell-off) can present a compelling buying opportunity. Unfortunately, this tends to materialize in the “rearview mirror” well after prices recover. A simpl... Read the Full Story |
|
From Our Partners | | Tesla's About to Prove Everyone Wrong... Again
Back in 2018, when Jeff Brown told everyone to buy Tesla…
The "experts" said Elon was finished and Tesla was headed for bankruptcy.
Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | | Click here to see why Tesla's about to prove everyone wrong... again. |
|
The Early Bird Stock Of The Day Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. | | View Today's Stock Pick |
|
